Table 1:
Demographic and Clinical Measures in Probands and Controls
| HC (n=60) | Probands (n=140) | |
|---|---|---|
| Age (mean, SD) | 37.6 (13.5) | 34.3 (13.3) |
| Sex (Male/Female) | 26/34 | 60/80 |
| Ancestry (EU/AF) | 46/14 | 97/43 |
| Diagnosis (SZP, BPP) | - | 79/61 |
| Antipsychotic (yes/no) | ||
| 1st Generation Antipsychotic | - | 14/124 |
| 2nd Generation Antipsychotic | - | 96/42 |
| Daily CPZ equivalent (mean, SD) | - | 504 (441) |
| Lithium (yes/no) | - | 21/117 |
| SSRI (yes/no) | - | 43/95 |
| Age of onset (mean, SD) | - | 15.8 (6.8) |
| Storage Days (mean, SD)* | 2398 (293.4) | 2523 (279.4) |
| Hemolysis score (mean, SD) | 1.9 (1.0) | 1.8 (0.9) |
| NSAID (yes/no) | 17/43 | 25/113 |
| CMDM (yes/no)* | 2/58 | 29/110 |
| CMD (yes/no)* | 4/84 | 45/86 |
| GAF (mean, SD)* | 84.5 (5.4) | 50.4 (12.9) |
| SFS total (mean, SD)* | 163.5 (17.6) | 130.8 (21.9) |
| PANSS Positive total (mean, SD) | - | 16.5 (5.8) |
| PANSS Negative total (mean, SD) | - | 16.7 (6.6) |
| YMRS total (mean, SD) | - | 6.8 (6.3) |
| MADRS total (mean, SD) | - | 11.1 (9.2) |
Note: SD = standard deviation; EU = European; AF = African; HC = healthy control; CPZ = chlorpromazine; SSRI = Selective Serotonin Reuptake Inhibitor; NSAID = non-steroidal anti-inflammatory agent; CMDM = cardiovascular medicine; CMD = cardiometabolic disorder; GAF = global assessment of function; SFS = Birchwood social functioning scale; PANSS = Positive and Negative Syndrome Scale; YMRS = Young Mania Rating Scale; MADRS = Montgomery–Åsberg Depression Rating Scale.
*
Proband group vs HC comparisons, p < 0.05